Detects human ENPP-1 in direct ELISAs and Western blots. In direct ELISAs, less than 3% cross-reactivity with recombinant human ENPP-2 and recombinant mouse ENPP-2 is observed after removal of cross-reactivity with human ENPP-2.
Polyclonal Sheep IgG
Mouse myeloma cell line NS0-derived recombinant human ENPP-2-1-2 Asp49-Trp144 (ENPP-2), Val191-Leu591 (ENPP-1), Asn532-Ile863 (ENPP-2). Cross-reactivity with human ENPP-2 was removed from the final product. Accession # Q13822 (ENPP-2) P22413 (ENPP-1)
Supplied in a saline solution containing BSA and Sodium Azide.
Alexa Fluor 488
5 µL/106 cells
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of ENPP‑1 in HepG2 Human Cell Line by Flow Cytometry. HepG2 human hepatocellular carcinoma cell line was stained with Sheep Anti-Human ENPP‑1 Alexa Fluor® 488‑conjugated Antigen Affinity-purified Polyclonal Antibody (Catalog # FAB6136G, filled histogram) or isotype control antibody (Catalog # IC016G, open histogram). View our protocol for Staining Membrane-associated Proteins.
Preparation and Storage
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Protect from light. Do not freeze.
12 months from date of receipt, 2 to 8 °C as supplied.
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP-1) is a transmembrane glycoprotein that hydrolyzes nucleotides and nucleotide derivatives with the formation of nucleotide-5’-monophosphates. It is inserted into the plasma membrane by an N‑terminal transmembrane domain. Human ENPP-1 has a small N-terminal cytoplasmic domain and a large C-terminal region containing two somatomedin B-like domains, a catalytic domain and a nuclease-like domain in the extracellular space (1). Defects in the ENPP-1 gene cause arterial calcification and bone mineralization abnormalities (2). ENPP-1 polymorphism or overexpression is also associated with obesity, type II diabetes and insulin resistance, which makes modulation of ENPP-1 activity one of the targets to treat insulin resistance and related diseases (1).
Goldfine, I.D. et al. (2010) Endocrine Reviews. 29:62.
Hessle, L. et al. (2002) Proc. Natl. Acad. Sci. 99:9445.